New Research Links Blood Test to Early Detection of Dementia in Women
Recent studies from the University of California San Diego suggest that a simple blood test could help identify women’s risk of dementia as much as 25 years before they show any symptoms. The research highlights a specific protein, known as phosphorylated tau 217 (p-tau217), which is closely related to the early stages of Alzheimer’s disease and could serve as a valuable indicator of future dementia.
The study analyzed blood samples from 2,766 participants, aged between 65 and 79, who were part of the Women’s Health Initiative Memory Study conducted in the late 1990s. At the beginning of the study, none of the participants exhibited signs of cognitive decline. After tracking these women for nearly 25 years, researchers found a significant link between higher levels of p-tau217 and an increased risk of developing mild cognitive impairment and dementia.
“This study indicates that we might be able to detect dementia risk decades in advance with a straightforward blood test,” said Aladdin H. Shadyab, the study’s lead author and an associate professor at UC San Diego. He emphasized that identifying who is at the highest risk can help in planning treatment strategies to delay or even prevent dementia.
The research revealed that women over 70 with elevated p-tau217 levels showed worse cognitive outcomes compared to younger participants. Additionally, those carrying the APOE ε4 gene, a known risk factor for Alzheimer’s, were also affected more severely.
The findings, published in JAMA Network Open, suggest that blood tests like p-tau217 are less invasive and could replace more invasive procedures like brain scans or spinal fluid tests. Linda K. McEvoy, a senior author on the study, stated that these blood-based biomarkers could significantly enhance our understanding of risk factors for dementia while also aiding in testing strategies aimed at reducing that risk.
While these promising results are encouraging, Shadyab cautioned that blood tests for Alzheimer’s are still being refined and aren’t yet recommended for routine use in asymptomatic individuals. More research is needed to determine how factors like genetics, hormone therapy, and age-related health conditions may affect p-tau217 levels.
It’s important to note that the study focused solely on older women, which means the results may not directly apply to men or younger groups. As the field evolves, future studies are expected to explore a broader range of populations and dementia types.
Overall, this new research brings hope for earlier detection and intervention in the fight against dementia, potentially paving the way for better health outcomes for future generations.
